✦ LIBER ✦

Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML

✍ Scribed by Litzow, Mr; Dietz, Ab; Bulur, Pa; Butler, Gw; Gastineau, Da; Hoering, A; Fink, Sr; Letendre, L; Padley, Dj; Paternoster, Sf

Book ID: 111674313
Publisher: Informa plc
Year: 2006
Tongue: English
Weight: 213 KB
Volume: 8
Category: Article
ISSN: 1465-3249
DOI: 10.1080/14653240600735743

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical-grade manufacturing of autologo

Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial

✍ Van Driessche, Ann; Van de Velde, Ann L.R.; Nijs, Griet; Braeckman, Tessa; Stein 📂 Article 📅 2009 🏛 Informa plc 🌐 English ⚖ 945 KB

Clinical-grade manufacturing of DC from

Clinical-grade manufacturing of DC from CD14+ precursors: experience from phase I clinical trials in CML and malignant melanoma

✍ Dietz, A.B.; Padley, D.J.; Butler, G.W.; Maas, M.L.; Greiner, C.W.; Gastineau, D 📂 Article 📅 2004 🏛 Informa plc 🌐 English ⚖ 122 KB

A phase I/II clinical trial of autologou

A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission

✍ Linn, Yeh-Ching; Yong, Hao-Xiang; Niam, Madelaine; Lim, Tsyr-Jong; Chu, Sixian; 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 227 KB

A phase I clinical trial of immunotherap

A phase I clinical trial of immunotherapy with interferon-γ gene-modified autologous melanoma cells : Monitoring the humoral immune response

✍ Zeinab Abdel-Wahab; Christina Weltz; Dina Hester; Nancy Pickett; Carol Vervaert; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 208 KB

and then 18 million for the fifth and sixth injections. The humoral immune responses of the patients were assessed by enzyme-linked immunoadsorbent assay, radioimmunoassay, and radioimmunoprecipitation. ## RESULTS. Thirteen of the 20 patients completed the immunization protocol. Eight of these 13

Phase IIA Clinical Trial to Test the Eff

Phase IIA Clinical Trial to Test the Efficacy and Safety of Toremifene in Men with High-Grade Prostatic Intraepithelial Neoplasia

✍ Steiner, Mitchell S.; Pound, Charlie R. 📂 Article 📅 2003 🏛 CIG Media Group, LP. 🌐 English ⚖ 145 KB

Specific active immunotherapy in patient

Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA). A phase I clinical trial

✍ Ariel Hollinshead; E. George Elias; Myron Arlen; Barbara Buda; Maria Mosley; Jos 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 838 KB

Twenty-two patients received specific active immunotherapy (TAA vaccine once per month for 3 months), with the duration of follow-up, as of July 1984, ranging from 3 months to 36 months (median, 21 months). Of these, seven had Dukes Bz, seven had Dukes C, and eight had Dukes D lesions. All received